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Acquired Immunodeficiency Syndrome (AIDS) is one of the most critically acclaimed endemic diseases, caused by
two lentiviruses HIV-1 and 2. HIV-2 displays intimate serological and antigenic resemblance to Simian
Immunodeficiency Virus (SIV) along with less pathogenicity, lower infectivity and appreciable cross reactivity with
HIV-1 antigens. The present era is confronted with the challenge to fabricate a vaccine effective against all clades of
both the species of HIV. But vaccine development against HIV-1 has proven highly intricate, moreover the laborious
and deficient conventional approaches has slackened the pace regarding the development of new vaccines. These
concerns may be tackled with the development of HIV-2 vaccine as a natural control of HIV-1 that has been found
in ancestors of HIV-2 i.e. African monkeys, mangabeys and macaques. Thereby, suggesting the notion of cross
protection among HIV-2 and HIV-1. Assistance of bioinformatics along with vaccinomics strategy can bring about a
quantum leap in this direction for surpassing the bottleneck in conventional approaches. These specifics together
can add to our conception that HIV-2 vaccine design by in silico strategy will surely be a constructive approach for
HIV-1 targeting.
Keywords: Human Immunodeficiency Virus-2, Vaccine Development, Bioinformatics, VaccinomicsIntroduction
The first acknowledged case that marked the commence-
ment of AIDS dates back to the late 19th century and ever
since it has been regarded as the most devastating pan-
demic with no definite cure available till date. It is the final
stage of an immunodeficiency disorder caused by a retro-
virus called Human Immunodeficiency Virus (HIV)
(Amadi et al. 2008). The origin of HIV, on the basis of in-
timate similarity is related to another kind of virus which
infected monkeys, known as the Simian Immunodefi-
ciency Virus (SIV) (Worobey et al. 2010).
AIDS is characterized by the selective targeting of the
CD4+/CD8+ T cells by HIV which fatally impairs the
immune system. The window period for this retrovirus
may last from several weeks to few months altogether
before the seroconversion (detection of earliest antibodies
in blood serum raised against HIV) (Taylor 2003). How-
ever, a person is said to be diagnosed with AIDS, only* Correspondence: diwan.batul@gmail.com
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in any medium, provided the original work is pwhen the CD4+T cell count drops below 200 cells/
microlitre, time period for which is indefinite and may
last from few months to years (Mandell et al. 2009). This
makes the immune system highly vulnerable to oppor-
tunistic infections.Human Immunodeficiency Viruses 1& 2
There are two closely related human lentiviruses causing
AIDS, referred to as HIV-1 and HIV-2 (Adam et al.
2007). Although HIV-1 is more common and prevalent
species of HIV, HIV-2 is relatively new and was discov-
ered in West Africa in 1986 (Clavel et al. 1986). It has
evolved as a result of independent cross species trans-
mission events from sooty mangabeys to humans (Clavel
et al. 1986). It is found to be more widespread in West
Africa, India and Europe infecting about 1 to 2 million
individuals (de Silva et al. 2008). Even though there are
few differences between HIV-1 and HIV-2 (Table 1),
both are perilous. HIV-1 and 2 shares various biological
and genetic properties such as genome structures, mech-
anism of trans-activation and manner of CD4+T celln Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.




Heterosexual Spread Higher Lower
Vertical Transmission 20-25% ≤5%
Genetic Diversity – Lower
Prevalence Global West Africa
Origin Common Chimpanzee Sooty Mangabey
Time to Aids ≤10 Years ≥20 Years
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lence properties of HIV-2 vary appreciably from HIV-1
and may range from comparative attenuation in certain
individuals to elevated pathogenicity in others (Reeves &
Doms 2002).
Although both viruses lead to immunodeficiency but
(Clavel et al. 1986) HIV-2 in contrast to HIV-1 exhibits
lesser rates of sexual transmission, slower disease pro-
gression , longer clinical latency periods lower viral load
in the asymptomatic stage (Sousa et al. 2002) and signifi-
cantly lower vertical and horizontal transmission rates
(Reeves & Doms 2002).
Strains of HIV-1 are classified as Group M, Group N,
Group O and Group P. Out of these, only group M is
broadly dispersed in the world whereas, HIV 2 has six
subtypes (or clades) ranging from A to F and of these,
subtype A is most prevalent (De Cock et al. 1993; Reeves
& Doms 2002). Studies have revealed a relatively resist-
ant response of HIV-2 infected individual towards con-
sequent HIV-1 infection (De Cock et al. 1993; Reeves &
Doms 2002). The similarities that exist between HIV-1
and HIV-2 can be exploited for the development of a
prospective vaccine which can potentially target HIV-1.
The underlying principle behind this approach is to
formulate a vaccine based on the conserved genetic
sequences that are present in HIV-2. As previously men-
tioned, HIV-2 infected individual provides a cross pro-
tection against HIV-1. So, it is thought that a vaccine
developed against HIV-2 can also show the caliber of
targeting HIV-1 (which is difficult to target otherwise
due to its highly mutative nature). This can be achieved
with the help of upcoming bioinformatic strategies
which is dealt in Later Section. The main advantage of
such an approach is that it saves a lot of time and energy
that is indispensably called for any wet lab approach
based on a similar concept.
Genetics
Although HIV-1 and HIV-2/SIV groups of viruses might
have genetically diverged from each other about 50 to
60 years ago (Chen et al. 1996) but they still show a gen-
etic similarity of about 40–50 percent (Sourial et al.2005). Primary, regulatory and accessory genes in HIV-2
are similar to that of HIV-1 with slight differences that
are discussed below:
A. Polymerase gene (pol): Three proteins are encoded
by pol of HIV-2: endonuclease/integrase (IN), protease
(PR) and reverse transcriptase (RT), which also has
RNaseH activity. Studies demonstrate that HIV-2 pol
shows comparable error prone propensity as that of
HIV-1 (Bakhanashvili & Hizi 1992) on the other hand,
its RNaseH activity is reported to be lesser by almost
10-folds than HIV-1 enzyme (Hizi et al. 1991).
B. Structural Genes (gag & env): Extremely conserved
gag proteins are basically same for both HIV-1 and
HIV-2 (Voss et al. 1992). A myristoylated 55-kDa
precursor cleaved by the viral protease generates the
capsid protein p24 (CA); the nucleocapsid protein p7
(NC); the matrix protein p17 (MA); p1; p2; and p6.
HIV-2’s envelope glycoprotein precursor is somewhat
smaller in contrast to HIV-1, hence at times it is
designated with lower sizes (i.e. gp140–145, gp105–110
and gp32–40 respectively).
C. Regulatory and Accessory Genes: RNA processing
or splicing is a vital control component apart from the
long terminal repeat (LTR) regions at the ends of the
viral genome containing crucial sequences for
transcriptional activation and termination. As
compared to HIV-1, HIV-2 has less responsive LTR to
cellular activation signals and has dissimilar response
elements (Popper et al. 2000). Also transcriptional
activation requires additional factors. These
differences along with lower CD4 affinity seen with
HIV-2’s gp120 may account for the reason that makes
HIV-2 infected individuals to have a lower viral load
than those infected with HIV-1 (Sousa et al. 2002).
Also HIV-2 shows enhanced sensitivity to
neutralization due to its ability to infect host cell
independent of CD4 interaction (Figure 1 & 2) (Reeves
& Doms 2002).
Studies also verify that among HIV-1 and HIV-2
infected individuals, T4 lymphocyte counts and T4:T8
ratios emerge to be declined less significantly in HIV-2
than in HIV-1 infected individuals (Kanki & Meloni 2004).
Genetic details of HIV-2 reveal many important factors
responsible for slow progression and less virulent nature
of HIV-2. Not only structural but also the regulatory genes
demonstrate varied activity and its host attachment affin-
ity is also lower compared to HIV-1 which might be the
prime reason of HIV-2’s reduced virulent nature.
These data all together indicate that it is comparatively
easier to target HIV-2 than HIV-1. Talking about immun-
ity against HIV-2, humoral and T-cell immune response
decline slowly compared to HIV-1 infected individual.
Figure 1 CD4 Dependent infection: Interaction between CD4 on T cell and viral gp120 leads to conformational changes in Env which further
brings about interaction between co receptor and virus which further leads to fusion of viral membrane and insertion of viral genome in a host cell.
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can be studied which can offer hints regarding the way
immune system reacts on its exposure.
Immunity
HIV-2 illustrates attenuated infectivity which has con-
stantly been a subject of curiosity among researchers for
understanding its immunopathogenesis. Also, studies
highlight the fact that the strong antibody response is
generated by infected people against antigens encoded
by gag, pol, and env (Chanock et al. 1987; Girard &
Valette 1988). The broadness of neutralizing antibody
reaction against HIV-2 is divergent from that of HIV-1
(Fenyo & Putkonen 1996). Cervicovaginal secretions of
infected women demonstrated that one-third of them
generated IgA response to HIV-2 envelope antigens con-
firming lesser viral replication as compared to HIV-1.
HIV-2 infected individuals also show prominent cross-
reactivity by IgG and IgA against heterologous envelope
antigens in contrast to HIV-1 for this compartment
(Belec et al. 1996). This might be the rationale behind
dissimilar heterosexual transmission rates for one type
of HIV in individuals infected by other type. ThisFigure 2 CD4 Independent infection: Interaction takes place directly bet
insertion process.elucidation maintains the belief that HIV-2 infection
protects against subsequent HIV-1 infection but not the
vice versa. While some predicted the exact contrary de-
tail that HIV-2 infection does not protect against con-
secutive HIV-1 infections (Greenberg 2001; Schim van
der Loeff et al. 2001). In depth studies on HIV-1 & HIV-
2 is required to conclude this debate and reveal several
hidden facts. Nevertheless, these perceptions of cross
protection among HIV-2 and HIV-1 can add to our
comprehension whether viral variability can be con-
quered for the design of broadly reactive vaccine candi-
date against all subtypes (or clades).
Necessity of Vaccine
Successful anti-HIV vaccine is an immediate need
considering its pandemic in certain regions of the world
including West Africa, China and Southeast Asia to halt
this wave of spread. But its development has been a
major challenge till date for scientists as HIV demolishes
immune system intended to fight against it, also its gen-
etic material remains in dormant form and thus escapes
the immune system. It has quite a few subtypes each dif-
fering from one another and even in each subtypes itween virus and co receptors to trigger membrane fusion and genome
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model exist for trials. However, non human primates
may possibly appear as a significant option (Bernstein
2010). Even after the advancement in medication pattern
new infections still persists and an effective vaccine is
required to completely stop its spread. Till date more
than 60 phase I, II and III trials are going on around the
world but a truly effective vaccine is still far away from a
stage where it can be said as achieved.
Hopes still persist for discovery of vaccine as many
researches and findings elucidate production of broadly
neutralizing antibodies targeting different types of HIV
which can be the basis for new research in the vaccine
development.
Conventional Attempts
Numerous ongoing researches have taken into account
various aspects for targeting HIV-2 each one of which
can notably contribute towards its targeting.
Five major subtypes (or clades) of HIV-2 from A to E
have already been reported to exist in certain human
population (Gao et al. 1994). But a new highly divergent
HIV-2 subtype (or clade) designated as F is the recent
addition to the presently existing classes supporting the
belief that new HIV-2 subtypes evolve from independent
cross-species transmission of SIVsm to the human popula-
tion (Smith et al. 2008). Comparative analysis of SIVsm
and HIV-2 with HIV-1 in the macaques model demon-
strated that pathogenic SIVsm infection was neutralization
resistant similar to HIV-1 infection in humans. On con-
trary, HIV-2 infected macaques remain susceptible to
neutralization and exhibit cross reactivity on account of
its steady biological properties (Laurén et al. 2006).
Vaccine trials carried out in macaque's model revealed
that active immunization with iscoms (immune stimulat-
ing complex) using native inactivated viral proteins
followed by iscom coupled V3 derived peptide booster
doses induced protective immunity against HIV-2 infec-
tion in cynomologus monkeys (Putkonen et al. 1994).
In another study, immunogenicity and neutralizing re-
sponse of recombinant envelope proteins derived from
the lone administration of reference primary HIV-2ALI
(one kind of HIV-2 isolate) or in different prime-boost
combinations in the mouse model was investigated. It
was found that broadly reactive HIV-2 Nabs can be
obtained by using a vaccinia virus vector-prime/rpC2-C3
(recombinant peptide containing C2 V3 C3 envelope
region) boost immunization strategy which suggested a
potential relationship between escape to neutralization
(Marcelino et al. 2010). Similarly, the efficacy of a re-
combinant HIV-2 canarypox (ALVAC HIV-2 which uses
canarypox virus which cannot harm human) vaccine
given alone or in combination with HIV-2 envelope
gp125 or HIV-2 V3 synthetic peptides was inspected in14 cynomologus monkeys. Four out of ten monkeys
immunized with ALVAC HIV−2 plus HIV-2 gp125 or
V3 peptides were found to be protected (Andersson
et al. 1996).
The aforementioned studies indicate the existence of
certain conserved regions in HIV-2 against which signifi-
cant immune response was seen in animal models. Sev-
eral experiments were done which not only verified this,
but also confirmed targeting capacity of some mono-
clonal antibodies specific to them. In a study done by
Mannervik M et al., synthetic peptides of external enve-
lope glycoprotein gp125 based on HIV-2SBL6669 were
used to recognize its continuous antigenic sites. It veri-
fied seroreactivity to few distinct linear sites on gp125
analogous to HIV-1 gp120 in case of molecular arrange-
ment (Marcelino et al. 2006). In another investigation,
neutralizing Ab’s targets for HIV-2 glycoprotein were
mapped strictly considering the function of V3 region.
Two discrete immunogenic sites were identified, first in
the area with the conserved motif Phe-His-Ser (amino
acid 315–317) second in the immediacy of the COOH-
terminal cysteine Trp-Cys-Arg (amino acid 329–331). It
was concluded that these two can possibly interact as a
single discontinuous site representing the importance of
V3 (Andersson 2001). These immunogenic sites in
V3-loop were further characterized and the significance
of different configurations of peptides corresponding to
this region was studied and attained outcomes main-
tained the hypothesis that the well conserved motifs of
the HIV-2SBL6669 V3 region i.e. FHSQ and WCR are cru-
cial targets for neutralizing antibodies. These motifs can
play a vital role for the designing of a potential HIV-2
vaccine (Dimonte et al. 2011; Morner et al. 1999).
On the other hand the role of humoral immunity in
the evolution of the HIV-2 env C2V3C3 regions was
examined in the context of their antibody response (IgG
and IgA) against it. IgG antibody against C2V3C3 effi-
ciently restricted viral population and escape while IgA
successfully targeted C3 region (Borrego et al. 2008). Re-
cently molecular, evolutionary and structural comparison
of the these envelope regions from both HIV-1 and
HIV-2 was done which suggested that in HIV-2 the V3
loop is much less exposed than C2 and C3 due to a
physical interaction with both whereas its conserved na-
ture is constant with lack of immunodominancy in vivo
(Barroso et al. 2011).
The capacity of antibodies against such conserved
domains was explored by generating them in rabbits
against HIV-2 V2 and V3 regions to interact with glyco-
sylated and deglycosylated protein, to hinder with gpl05-
CD4 interface. It revealed that V2 and V3 regions are
not directly involved in the gp105 binding site for the
CD4 receptor (Babas et al. 1994). The production and
characterization of MAbs (monoclonal antibodies)
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2ROD suggested that the V3 region of HIV-2 has a simi-
lar function to that of HIV-1 in the infection process
differing from earlier result which indicated lack of
immunodominancy of V3 and specified that V3 se-
quence of HIV-2 may be a useful target in an animal
model for HIV vaccine development (Matsushita et al.
1995). In addition, the neutralization capacity of the
purified anti HIV-2 V3 MAbs i.e. conformation-sensitive
(3C4) and a linear site-specific (7C8) and their respective
papain-generated Fab fragments suggested that whole
7C8 and 3C4 MAbs were sterically hindered from neu-
tralizing HIV-2. Alternatively the smaller size of Fab
fragments capably accessed the virion surface V3 region
(Sourial & Nilsson 2008). Further proceeding in this dir-
ection, the crystal structure of the Fab fragment of 7C8
was presented for structural analysis which showed a
deep and narrow highly hydrophobic antigen-binding
cleft (Uchtenhagen et al. 2011).
Some distinctive details apart from the existence of
conserved residues and generation of neutralizing anti-
bodies against them were also revealed which might be
valuable in some way or other. H. Akimoto et al., found
that the envelope glycoprotein of HIV-2 (not of HIV-1),
could bind to CD4 and CD8 molecules on T cells α-
chain (but not the P-chain) and induce phosphorylation
of protein tyrosine kinase p561ck(lymphocyte specific
protein tyrosine kinase) in CD8+ T cells. Also produc-
tion of β-chemokines in response to HIV-2 envelope
glycoprotein was significantly higher as compared to the
response to HIV-1 envelope glycoprotein which was
related to signal transduction into CD8+ T cells and the
resultant β-chemokines production in HIV-2 infection.
This might explain the difference in virulence and dis-
ease manifestations between HIV-1 and HIV-2 infection
(Cavaleiro et al. 2000).
Apart from envelope region gag was demonstrated to
be most immunogenic specifically p26 region. The
steady rapport between Gag specific immune responses
and viral regulation indicated that, T cell responses are
crucial in determining the better outcome of HIV-2 in-
fection which may add to the understanding of relation
between HIV-2 controlled infection and protective im-
munity for the design of HIV vaccine (Leligdowicz et al.
2007). Comparison of homologous and cross reactive
Gag-specific T-cell responses between HIV-1 and HIV-2
infected patients for their gag peptides revealed that
homologous Gag-specific T-cell responses were broader
and stronger in HIV-2 infected patients as compared to
HIV-1. In contrast cross reactive T-cell response was
narrower and weaker in HIV-2 as compared to HIV-1
infected patients. This cross reactive response indicated
HIV-1/HIV-2 Gag sequence similarities. Thus HIV-2-
specific T-cell responses control HIV-2 replicationrestraining viral diversification (Jennes et al. 2008). The
capsid region of Gag may be better processed and
presented on MHC in contrast to other viral proteins
moreover antigens from this region, might be more
exposed to be presented as capsid, is generally expressed
in higher levels (Chertova et al. 2006). A further examin-
ation reported another strategy for HIV-2 targeting.
Genomic RNA dimerisation is facilitated by a sequence
positioned within the Psi region and that dimerisation
may certainly be linked to viral packaging thus dimerisa-
tion defective viruses will be deficient in virion matur-
ation and infectivity, possibly presenting new targets for
HIV-2 replication inhibition (L'Hernault et al. 2007).
These essential demonstrations indicate cross reactiv-
ity, strong antigenicity by conserved domains especially
V3, antibody response against them and generation
of anti-HIV-2 V3 mouse MAbs i.e. 3C4 and 7C8. Also
the difference in signal transduction in HIVs, gag spe-
cific T-cell responses and dimerisation defective HIV-2
(deficient in maturity and infectivity) give minute details
about HIV-2 which can prove stepping stones while aim-
ing it and AIDS. But these essentials alone can’t be suffi-
cient, as some novel strategic effort which can use the
above facts in a quicker way for rapid prediction of vac-
cine, is the need of the hour.
Future Aspects
The search for an effective AIDS vaccine is the most
daunting task because of the variable and divergent
characteristic of the virus along with extremely long and
time taking protocols for vaccine development which
calls for a minimum duration of 6-10 years. Till today
vaccine development program has reached up to phase 3
trials for HIV-1 but no validated vaccine against HIV-1/
HIV-2 has been developed. The difficult and deficient
character of these approaches is an obvious obstacle
towards developing new vaccine.
Application of reverse vaccinology can be a possible
strategy to overcome the aforementioned obstacles and
surmount these challenges. It offers a promising vaccine
development approach starting with the prediction of vac-
cine targets by bioinformatics scrutiny of pathogenic gen-
ome sequences (Rappuoli 2000). Predicted protein targets
for instance, envelope protein etc. are chosen on the basis
of desirable features after which normal wet laboratory
trials could be carried out for testing the selected targets
(Pizza et al. 2000; Rappuoli 2000) which reduces both time
and cost of development. Also, other upcoming fields of
vaccine research like vaccinomics including pharmacogen-
omics, pharmacogenetics as well as bioinformatics has
proved beneficial in novel vaccine target prediction for
extremely variable pathogens (Sirskyj et al. 2011). More-
over, synthetic peptides could be designed resembling the
immunogenic or conserved domains of hyper variable
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ging softwares for immune responses.
In one such study, two computer-driven methods for
improving epitope-driven HIV vaccines: the Epi-Assem-
bler, for deriving "immunogenic consensus sequences"
(ICS) epitopes from multiple viral variants, and Vaccine
CAD , which reduces junctional immunogenicity between
epitopes for insertion in a DNA expression vector, were
selected. They were used for selection and construction of
novel “immunogenic consensus sequence” T cell epitope-
driven HIV vaccines (De Groot et al. 2005). Further com-
putational modeling was applied for recognition of
chimeric HRV (Human Rhinovirus type 14) constructs.
They preferentially displayed the epitope in the same β-
turn conformation as already depicted in the crystal struc-
ture of complex with 2 F5 and chimeric HRV displaying
the 2F5 epitope of HIV-1 gp41 (called ELDKWA after its
core sequence). It signified the prospect of eliciting pro-
tective immune responses (Lapelosa et al. 2009).
Many web based servers and softwares have been
developed in the recent past which can efficiently pre-
dict epitopes and consensus sequence proving to be a
quantum leap in the direction of vaccine development.
MHCPEP is a curated database comprising over 4000
peptide sequences known to bind MHC molecules.
Entries are compiled from published reports as well
as from direct submissions of experimental data
(De Groot et al. 2002). PEPVAC (Promiscuous EPitope-
based VACcine), optimized for the formulation of
multi-epitope vaccines with broad population coverageFigure 3 Application of Bioinformatics tools for HIV-2 and AIDS vacci
HIV-1 and hence HIV-2’s conserved genomic regions could be utilized for t
prediction tools and other softwares can ease this task and hence can mak
development.(Reche & Reinherz 2005). Vaxign is the web-based vac-
cine design system for prediction of vaccine targets
based on genome sequences using the strategy of re-
verse vaccinology. Predicted features comprise of pro-
tein sub cellular location, transmembrane helices,
adhesion probability, conservation to human and/or
mouse proteins, sequence exclusion from the genome
(s) of nonpathogenic strain(s), and epitope binding to
MHC class I and class II (He et al. 2010). Several other
algorithms and databases for vaccine prediction are
(Sirskyj et al. 2011):
 EpiMatrix (EpiVax Inc): Predicts epitopes for over
numerous MHC class I and II alleles.
 BlatiMer: Automated BLAST search tool.
 Conservatrix: Finds conserved epitopes.
 PAP: Predicts protein sequences which can be
antigenic by generating an antibody response
 SYFPEITHI: Database having numerous peptide
sequences showing binding affinity with MHC class
I and II molecules.
Modern strategies using in silico approaches will defin-
itely be more quick, cost effective and may prove worthy
in finding vaccine targets for HIV-2.
Conclusion
HIV-2 is slow progressing, less virulent and less mortal as
compared to HIV-1. But certain striking features make it a
promising vaccine candidate for targeting both HIV-1 & 2ne prediction: HIV-2 infected individuals exhibit cross protection to
argeting HIV-1 also. Bioinformatic tools, web servers like epitope
e the approach novel, rapid and effective for AIDS vaccine
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of HIV-1 in African monkeys (believed to be ancestors of
HIV-2), existence of certain extremely conserved domains
in it against which neutralizing antibody response has
been observed i.e. envelope proteins as well as gag. Thus
detailed considerations of HIV-2 can guide us towards a
profound understanding of both viruses which can prove
a landmark for design of a competent vaccine for AIDS
But conventional approaches are not entirely capable of
dealing with various complications that arise during the
development of new vaccines. Therefore the future of vac-
cine prediction lies in the union of current approaches like
reverse vaccinology, vaccinomics by means of bioinfor-
matics tool, web servers and softwares along with conven-
tional approaches (Figure 3). This unification of existing
conventional approaches with the above mentioned new
strategies for predicting vaccine against HIV-2 will cer-
tainly be helpful in the lane of vaccine development
against HIV-1 and AIDS which undeniably will be a future
benediction to mankind.
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